Search

everythinglearnresearchcommunity

for

Search:↓

Some people may not respond to topical minoxidil due to low SULT1A1 enzyme activity, but oral minoxidil can be effective. Tretinoin may enhance minoxidil's effectiveness, and some users prefer oral minoxidil despite side effects.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

A 26-year-old is considering switching from a finasteride and minoxidil blend to using dutasteride and minoxidil separately, with concerns about shedding and dosage changes. They are exploring options for sourcing and considering using ketoconazole shampoo to manage dryness.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

RU58841 powder is discussed for hair loss treatment, with suggestions to use a 5% solution in isopropyl alcohol. One user mentions using RU injections directly to the scalp.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

Hair loss treatments like finasteride, minoxidil, and RU58841 are becoming more known, but many remain unaware of their effectiveness. There is hope for future advancements despite skepticism and misconceptions about current treatments.

Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

A 27-year-old male is using minoxidil 5% nightly and alternating between three hair serums during the day, seeking advice on whether this routine is beneficial or overly complicated. Responses suggest simplifying the routine by focusing on minoxidil, possibly increasing its concentration, and considering finasteride or dutasteride instead of multiple serums.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

Exploring the effectiveness of redensyl, a hair loss treatment, compared to minoxidil and finasteride. People shared experiences using redensyl and products containing it, such as The Ordinary Hair Serum.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are curious about the effectiveness of products from Rokchem.co.uk.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

A 68-year-old is experiencing increased hair loss despite using Minoxidil and is seeking alternative treatments. Suggestions include considering finasteride or RU58841 as potential options.

The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The user has been using oral finasteride for 15 months and oral minoxidil for 6 months, and developed alopecia areata, for which a dermatologist prescribed calcipotriol/betamethasone. The treatment is helping, but the user is experiencing another shedding phase and is concerned about the effects of the steroid cream and the cause of hair loss.

The user is considering using RU58841 and pyrilutamide for hair loss, debating between powder and topical forms, and is currently using a combination of dutasteride, finasteride, minoxidil, tretinoin, and supplements. They report no significant side effects from finasteride and dutasteride, and are seeing some hair growth, but not on the scalp.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

The user is treating androgenetic alopecia with finasteride and discovered a folic acid deficiency. They are asking if curing the deficiency can worsen or improve their hair condition.